Kelly Ansems, @CochraneHaem: "Remdesivir probably has little or no effect on all-cause mortality at up to 28 days in hospitalised adults w SARS-CoV-2 infection. We are uncertain about the effects of #remdesivir on clinical improvement and worsening." https
The @CochraneHaem authors found 5 studies w 7452 people hospitalised w #COVID19. Of these, 3886 people were given #remdesivir. Average age of patients: 59. Studies took place around the world, mainly in high- and upper-middle-income countries. https://t.co
#Remdesivir is a medicine that fights viruses. It has been shown to prevent the virus that causes #COVID19 (SARS-CoV-2) from reproducing. Medical regulators have approved remdesivir for emergency use to treat people with COVID-19. https://t.co/ntgfDQjMqs
JUST PUBLISHED - Is #remdesivir an effective treatment for #COVID19? https://t.co/ntgfDQjMqs This @CochraneHaem systematic review looked at this antiviral medicine to see if it's an effective treatment for people in hospital w #COVID & if it causes unw
New #Cochrane Review Remdesivir for the treatment of COVID-19 Published 5 August 2021 (7/x) https://t.co/IdbL5tkngq
コクランからレムデシビルのレビューが出ました。やはり単剤では効果が限定的なようですね。 https://t.co/sBRxJ41aWX